Monday, 2 March 2015

08:00

Registration

09:00

Inauguration


Plenary Session

09:15

Alain BernardKeynote Presentation

Biotech Industrial Process : How Science, Technology and Market Demand meet
Alain Bernard, Vice President, UCB Pharma SA, Belgium

This presentation will highlight the Novel Strategies developed by Pharmaceutical Industry to improve Manufacturing process. It will focus on the safe implementation of Biotechnology Process changes along with maintaining product quality and comparability which has eliminated concerns of lack of capacities. Further, it will discuss the new challenges facing the industry with novel product formats and novel therapy paradigms.

10:15

Coffee Break and Networking Session


SESSION 1: Cell Culturing Strategies and Cell Line Optimization/ Session Chair: Pravin Potdar

10:45

Cell Culture Overview and Challenges in Upstream Process Development
Kriti Shukla, Principal Scientist, Biocon Research Limited, India

The talk will address the basics of cell culture and challenges that are encountered during upstream process development (PD) and how that impacts the development of a drug. This will cover important PD parameters such as approach towards product quality, productivity, process platform and associated challenges. 

11:25

Development & Characterization of Glioma Stem Cell Lines and Application of these Cell Lines as a Tool for Screening Anticancer Activity
Padma Shastry, Scientist, National Centre for Cell Science, India

This talk will discuss about development and establishment of primary cell lines and cultures from High Grade Gliomas. Further, it will explain the development and use of 3D- multicellular Spheroids (MCS) cultures and will highlight the potential of these cell lines/cultures as models for screening  potential anticancer compounds/agents.

12:05

Developing and Utilizing 3D Culture Systems for New Target Discovery/Cell Based Assays
Praveen Reddy, Scientific Manager, Biocon Ltd, India

This talk will discuss about the development  of 3D Culture Systems along with its advantages over 2D Culture Systems. In addition, this talk also highlights the pharmacological studies of Drug Candidates for New Target Discovery. Further, in this talk the necessity of High-Content Screening coupled with automation will be emphasized.

12:45

Lunch Break and Networking Session


SESSION 2: Cell Based Assays in Biomedical Research/Session Chair: Jeremy Simpson

13:30

Anthony Mitchell DaviesKeynote Presentation

Implementing Phenotypic Cell Based Assay and HCI in Translational Research! Choosing Right Tools for the Job.
Anthony Mitchell Davies, Director, Trinity College Dublin, Ireland

14:30

Choosing the Right Cell-Based Assays for Drug Discovery
Suresh Juluri, Assistant Director, Jubilant Biosys Ltd. , India

In this talk, the broad target classes and their appropriate cell based assays will be covered. It will also highlight the value of Phenotypic Screening and importance of establishing target engagement in primary cell types. Further, advantages and caveats of cellular assays will also be discussed.

 


SESSION 3: Advanced Cell Based Screening Techniques/Session Chair: David Hay

15:10

Cell based Assays and Screening Technologies
Shahab Uddin, Technology Manager, Centre for Cellular and Molecular Platforms, India

This presentation will highlight model assay system, advances in assay chemistries and signal detection technologies to be considered when choosing cell-based assays for automated systems. Further, it will discuss how these assay systems in use for drug target validation and ADMET studies can provide more representative responses to in-vivo conditions. In addition, it will throw light on 3D Cultures along with their advantages.

 

15:50

Stephen BrownKeynote Presentation

Cell-Based Assays and Screening Techniques: A User's Guide
Stephen Brown, RNAi Facility Screening Manager, Sheffield University, United Kingdom

This talk will lay emphasis on Cellular Assays Development and the quality of screens. Also, various related facilities will be discussed along with their merits and pitfalls. Further, in this talk data from number of screens will be presented along with the metrics used. 

16:50

Complex Cell- and Tissue-Based Model Systems for Phenotypic Drug Discovery - Investigating the Functional Role of the Tumor Microenvironment
Matthias Nees, Group Leader, University of Turku, Finland

In this talk, the goal of cell culture model system to address tumor/stroma will be presented. The application of High Content Screening approaches and automated image analysis software tools for identifying critical cell-cell-interactions and Phenotypic Drug discovery will also be covered. Further, complex organotypic assays will be discussed to understand may of the dynamic functions of living tissues in vitro.

17:30

End of First Day of Conference

Tuesday, 3 March 2015


SESSION 4: Advances in Cell Culture and Development/ Session Chair: Padma Shastry

09:00

Jeremy SimpsonKeynote Presentation

Genome-Wide High Content Screens of Cell Function and Behaviour
Jeremy Simpson, Vice Principal, University College Dublin, Ireland

In this presentation, genome-wide RNA interference and automated high content screening microscopy will be discussed which helps in systematically dissecting secretory, endocytic and retrograde pathways and quantifying the relevance of all genes to them. Particularly, regulatory networks spanning each of these pathways will be focussed. Further, the advantages of information obtained from these screens will be covered.

10:00

Assay Miniaturization Strategies: Smaller and Cheaper Cell-Based Assays for HCA
Anthony Mitchell Davies, Director, Trinity College Dublin, Ireland

This talk will discuss regarding assay miniaturization for large-scale High-Content Screening along with its advantages and other related issues.

10:40

QbD Approaches in Cell Culture Process Development
Alain Bernard, Vice President, UCB Pharma SA, Belgium

In this Presentation, various strategies and approaches for designing and developing manufacturing processes will be discussed for optimization of quality of the process and the product. In addition, it will also report and define process development space based on a rigorous risk analysis. Further, various process parameters and how they may affect product critical quality attributes will also be covered. Finally, the remaining open issues and outcomes of this approach will be presented.

11:20

Coffee Break and Networking Session


SESSION 5: Advances in Stem Cell Based Systems/ Session Chair: T R Raju

11:40

David HayKeynote Presentation

Delivering Functional Hepatocytes from Pluripotent Stem Cells
David Hay, Professor, University of Edinburgh, United Kingdom

This Keynote Talk will present the most recent advances in Stem Cell based Systems. It will emphasize on various Differentiation procedures for Pluripotent Stem Cells and will also discuss how Stem Cell derived hepatocytes are scalable and can metabolize Drugs.

12:40

Identifying and Validating Cellular Targets of Cancer using Somatic Stem Cells
Prithi Rajan, Adjunct Faculty- Chemical Physiology, The Scripps Research Institute, United States of America

This talk will discuss a couple of ideas where novel targets related to cancer, specifically gliomas, are studied using somatic stem cells along with other primary cultures.   Neural and mesenchymal stem cells are used as experimental paradigms to explore alternative activation of the Stat signalling pathway, and potential interactions between cells within the tumor vis-à-vis immune reactions.  The use of stem cell technology to study the cancer and stem cell states will also be discussed.  

13:20

Lunch Break and Networking Session

14:20

Poster Evaluation


SESSION 6: Stem Cells and CTC Strategies for Cancer/ Session Chair: K P R Pramod

14:40

Pravin D PotdarKeynote Presentation

Circulating Tumor Cells – Isolation, Characterization and Applications for Diagnosis & Therapies for Breast Cancer
Pravin D Potdar, Head, Jaslok Hospital & Research Centre, India

This presentation will over view the important technologies involved in isolation, characterization & application of CTC in breast cancer diagnosis & therapies.

15:40

The ‘Stem’ Of Cancer Chemoresistance- Targeting Cancer Stem Cells via the Wnt-Beta Catenin Pathway
Sudha Warrier, Associate Professor, Manipal Institute of Regenerative Medicine, India

This presentation will explore the effect of the Wnt antagonist, secreted EMT in CSCs in gliomas. It will also highlight how sFRP4 acts through the Wnt- ß-Catenin and the Wnt- calcium pathways in inhibiting CSCs. Further, it will discuss about designing better targeted strategies to improve chemo-response and eventually eliminate glioblastoma CSCs.

16:20

Sensitization of Pancreatic Cancer Stem Cells to Gemcitabine by Chk1 Inhibition
Venkatesha Venkatasubbaiah, Independent Consultant, Piramal Life Sciences Ltd, India

This Presentation will focus on the how Chk1 Inhibition sensitizes Pancreatic Stem Cells and Tumours to Gemcitabine. Further, it will also discuss about the finding how Chk1-mediated DNA damage response was greater in stem cells than in non–stem cells which  makes Chk1 a potential therapeutic target for improving pancreatic cancer therapy.

17:00

End of Conference